Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

What studies have been performed to demonstrate the efficacy of Rhophylac® in ITP?

April 26, 2017demonstrate ITP Performed rhophylac®

0

Posted

What studies have been performed to demonstrate the efficacy of Rhophylac® in ITP?

1 Answer

0

Posted

A. In a study conducted in Europe and the US, 98 Rho(D)-positive adults with chronic ITP and a platelet count of 30,000/microliter or less were treated with Rhophylac®. Patients received a single IV dose of 250 IU (50 mcg) per kg body weight. Overall, 66% of patients responded with a platelet increase of at least 20,000 to 30,000/microliter. A regression of hemorrhage was seen in 88% of the 50 subjects having bleeding at baseline. Learn more about the efficacy of Rhophylac®.